Why Drugmakers Pay Billions for Peptides: Deals, Stages and Safety Guide

Short answer: A Wall Street Wire article on Markets Insider (Nov. 9, 2026, a paid placement) reads the deals as buyers paying for candidates designed to improve on what exists. That is the article’s interpretation, not a finding. Samsung Biologics also pointed to rising demand for peptides in obesity and diabetes, GLP-1 therapies included, when it reported the PolyPeptide tender-offer result in early November. Below you will find what each buyer got, how far each drug is from testing in people, and how an FDA-approved peptide medicine differs from a research chemical sold online.

Quick facts as of 2026-11-09

Every row except argenx’s comes from the Wall Street Wire article on Markets Insider dated November 9, 2026, which cites company releases. That article is a paid placement, and Palatin is a paid subscriber to Wall Street Wire’s Market Discovery Program. The argenx row comes from argenx’s acquisition press release and BioPharma Dive coverage published the same day.

Why drugmakers want peptides now

BioPharma Dive explains that macrocyclic peptides are bigger and more intricate than typical small-molecule drugs, so they can grip hard-to-reach protein targets, yet they are small enough to be swallowed. Leerink Partners analyst Thomas Smith called the argenx deal “potential for longer-term strategic value.” He said pharma demand is strong for oral, long-acting treatments that might outperform conventional biologics on effectiveness and convenience.

Earlier macrocyclic-peptide medicines give these buyers a precedent to point to. BioPharma Dive lists Imcivree (Rhythm Pharmaceuticals, FDA-approved in 2020 for certain genetic forms of obesity), Lupkynis (Aurinia, 2021, the first oral medicine for adults with active lupus nephritis) and Zilbrysq (UCB, 2023, generalized myasthenia gravis).

What argenx is buying from Unnatural Products

argenx, a Netherlands-based company listed as ARGX on Euronext and Nasdaq, has agreed to buy Unnatural Products, Inc. (UNP) of Santa Cruz, California. It already holds a minority stake and will acquire the rest. Under the terms in argenx’s acquisition press release, argenx pays $550 million upfront in cash on hand, plus up to $595 million more if specified development and regulatory milestones are met. Total potential consideration is up to about $1.15 billion. Both boards have approved the deal, which is expected to close by the end of 2026, subject to customary closing conditions.

UNP pairs parallel experimentation with machine learning to design macrocyclic peptides aimed at hard-to-drug targets. argenx plans to use the platform to pursue oral or long-acting medicines for serious immune-mediated diseases. UNP’s team stays in Santa Cruz, which becomes argenx’s peptide discovery hub, while argenx takes on clinical development and commercialization. argenx’s CEO, Karen Massey, called UNP’s macrocyclic peptide skills “highly complementary” to argenx’s antibody engineering, and noted the two companies have worked together for more than two years.

BioPharma Dive reports that UNP has research or licensing ties to Merck & Co. and Novartis and raised a $45 million Series B. For context, it notes that argenx’s Vyvgart, also used for generalized myasthenia gravis, brought in $4.5 billion in net product sales from January through September 2026, citing argenx.

What the other deals bought

• Gilead and PepStar (agreed October 22, 2026). Gilead agreed to pay $1.275 billion in cash for HCXT-2001, an investigational oral peptide IL-23R inhibitor for inflammatory bowel disease, from privately held PepStar Therapeutics. The program is in Phase 1, the first stage of testing in people. The article reports that no milestones were disclosed and that the full amount is due at closing.
• Samsung Biologics and PolyPeptide (reported November 2 and 5, 2026). Samsung Biologics reported tender-offer results of about 98% (97.99%) for PolyPeptide Group, a Swiss peptide maker valued around 1.46 billion Swiss francs (about $1.77 billion). Regulatory approvals and closing are still pending. Samsung cited growing peptide demand, especially in obesity and diabetes, including GLP-1 therapies.
• AstraZeneca and CSPC (January 2026). AstraZeneca agreed to pay CSPC Pharmaceuticals $1.2 billion upfront for a portfolio of once-monthly injectable weight-management programs. The lead candidate was entering Phase 1.
• Pfizer and Metsera (completed November 2025). Pfizer completed its acquisition of Metsera, worth up to about $10 billion including contingent payments. The deal followed a bidding contest with Novo Nordisk and covers injectable obesity drugs dosed weekly or monthly.

Palatin’s MC4R peptides (paid placement)

This section draws on the Wall Street Wire article, which is a paid placement. Palatin is a paid subscriber to Wall Street Wire’s Market Discovery Program.

Palatin Technologies (NASDAQ: PTN) is building next-generation peptides aimed at the melanocortin-4 receptor (MC4R), which is involved in hunger and energy balance. Its first targets are acquired hypothalamic obesity, Prader-Willi syndrome and Bardet-Biedl syndrome. The article notes that Imcivree is approved for acquired hypothalamic obesity in the US, EU, UK and Japan.

Palatin’s CEO, Carl Spana, has said MC4R agonism is “clinically and commercially validated.” The article also lists gastrointestinal side effects and skin darkening (hyperpigmentation) as ongoing challenges for the category.

The lead program is a lipidated peptide from Palatin’s PL2000 series. According to the company, it reduced food intake and body weight with once-weekly dosing in obese mice, and early pharmacokinetic data support once-weekly or less frequent dosing in humans. The article also reports a 2025 Phase 2 obesity study in which bremelanotide (Vyleesi, FDA-approved in 2019 for hypoactive sexual desire disorder) was combined with tirzepatide: 40% of participants reached at least 5% weight loss, against 27% on tirzepatide alone (company-reported).

Next come IND-enabling studies, the preparatory work before a first human trial. A Phase 1 start is targeted for the first half of 2027, with initial data in the second half of 2027. The article also says Palatin has disclosed going-concern uncertainty and will need additional funding.

Do these deals prove a peptide is safe or works?

Deal prices show what buyers agreed to pay. Neither the price nor the stage of these drugs tells you whether they are safe or work in people. The UNP deal buys a macrocyclic peptide discovery platform, and neither source gives clinical data on any UNP drug.

The deals do show where buyers are looking: obesity and weight management, serious immune-mediated diseases, and oral or long-acting dosing. For what human studies of peptides have found, see our guide to peptides human studies (our research library).

The GLP-1 eye warning is separate news

On November 9, 2026, the FDA said it is requiring safety labeling changes for all GLP-1 receptor agonist (GLP-1 RA) medicines. The labels will add information about a potential increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition. Read the FDA’s drug safety communication for the full text. GLP-1 medicines are a different category from the macrocyclic and MC4R peptides above.

Label changes do not always change behavior quickly. A 2012 systematic review of FDA risk communications, published in Medical Care, found that some had immediate, strong effects on medicine use, while many had delayed effects or none on health care use or health behaviors.

What NAION is and what to watch for

FDA describes NAION as a rare condition that can cause acute, painless loss of vision in one eye, sometimes permanent. The symptoms FDA lists are sudden, painless vision loss in one eye, often noticed on waking; blurred or missing parts of vision, such as blind spots or tunnel vision; distorted colors; and reduced central sharpness. Contact a health care professional right away if you notice any of these.

FDA says NAION happens when blood flow to the front of the optic nerve drops, and that its underlying cause is not fully understood. Risk factors it names include smoking, diabetes, high blood pressure, sleep apnea, anemia and kidney disease. If NAION has occurred in one eye, the other eye faces a higher risk.

What the FDA numbers mean

FDA points to a meta-analysis of 126 randomized controlled trials with 134,253 patients. It counted 15 probable NAION events: 10 on GLP-1 RA medicines and 5 on placebo. Incidence was 6.4 per 100,000 person-years on GLP-1 RAs, compared with 3.8 per 100,000 on comparators. A person-year is one person followed for one year, so 6.4 means about 6 cases for every 100,000 people followed for a full year.

In FDA’s Sentinel cohort of adults with type 2 diabetes who started a GLP-1 RA or another diabetes drug between 2019 and 2024, NAION incidence ran from 26 to 32 per 100,000 person-years. Compared with DPP-4 inhibitors, GLP-1 RA use had a hazard ratio of 1.43 (95% CI 1.02 to 2.01). Compared with SGLT-2 inhibitors, FDA found no statistically significant increase (HR 1.19, 95% CI 0.91 to 1.54). FDA cites a general-population incidence of 2.3 to 10.2 per 100,000 persons per year in adults older than 50, and says NAION cases have been reported for all currently marketed GLP-1 RA products.

Who it affects

The label change covers all GLP-1 RA medicines. FDA lists their uses as type 2 diabetes; reducing excess body weight and keeping weight reduced; lowering the risk of major cardiovascular events in adults with known heart disease and with obesity, overweight or type 2 diabetes; lowering the risk of worsening kidney disease, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease; moderate to severe obstructive sleep apnea in adults with obesity; and MASH with moderate-to-advanced liver scarring. If you have a NAION event on one of these medicines, FDA says to talk with your health care professional about whether to continue or stop it.

FDA-approved peptide medicine vs research chemical sold online

FDA’s safety communication includes a table of approved GLP-1 RA medicines. It covers that one drug class only.

FDA notes that tirzepatide is a GIP and GLP-1 receptor agonist. Each name in this table is an FDA-approved GLP-1 RA medicine, and FDA is adding the NAION information to the Warnings and Precautions section of their labels. This table lists only the FDA-approved GLP-1 RA medicines from the FDA communication. Other peptide drugs, such as Imcivree and Vyleesi, are also FDA-approved. For any other product, ask a pharmacist or prescriber to check its approval status.

If you have a peptide product you are unsure about, take its name and label to your pharmacist. For a plain look at unapproved peptides, read unapproved peptides: safety and evidence. For one product’s FDA status, see the Semax peptide FDA status guide.

Common mix-ups

• “Peptide” covers three different things. GLP-1 RA medicines are approved drugs. Macrocyclic peptides are a class that already includes approved medicines, and the UNP deal buys a discovery platform. MC4R peptides like Palatin’s are preclinical.
• Deal size and drug stage are separate. Gilead’s program is in Phase 1, and the argenx deal is expected to close by the end of 2026.
• Pending deals are still open. The Samsung and PolyPeptide deal still needs regulatory approvals and closing.
• Paid placement sits next to news. The Palatin section comes from a paid placement, and the Gilead, Samsung, AstraZeneca and Pfizer rows come from the same article.
• The GLP-1 warning is its own story. It applies to the medicines in FDA’s table and is separate from the peptide deals.

Questions that settle your next step

1. Do I take a GLP-1 RA medicine? Check the name against the table above, then ask your prescriber or pharmacist what the new label means for you. Do not stop a medicine on your own.
2. Have I noticed sudden, painless vision loss, blind spots, distorted colors or blurred central vision? Contact a health care professional right away, and ask for an eye doctor (ophthalmologist) evaluation.
3. Is the product I am looking at an approved medicine? If it is a GLP-1 medicine, compare its name with FDA’s table. For any other product, ask a pharmacist or prescriber about its FDA approval status.
4. Do I want to report a problem? Report it to FDA MedWatch online or by calling 1-800-332-1088.

By HealthDataConsortium.org Research Team

This article is for general information purposes only and does not constitute medical advice. Consult your doctor or qualified healthcare provider before making changes to your health routine.